MedTrace Logo

A Bioavailability Study Comparing 3 Different AZD1981 Tablets

NCT01311635 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2011-07-07

No results posted yet for this study

Summary

The purpose of this study is to study the relative bioavailability of AZD1981 when using a new tablet compared to the current tablet.

Conditions

  • Healthy

Interventions

DRUG

AZD1981, current small-particle tablet

3x100 mg per oral, single dose in fasted state

DRUG

AZD1981, new small-particle tablet

3x100 mg per oral, single dose

DRUG

AZD1981, new large-particle table

3x100 mg per oral, single dose in fasted state

Sponsors & Collaborators

Principal Investigators

  • Wolfgang Kühn, MD · Quintiles AB, Phase 1 Services

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311635 on ClinicalTrials.gov